AnalytischDenker schreef op 12 april 2021 17:02:
[...]
Cosmo Pharmaceuticals heeft bij de equity swap in juni 2020 zelfs € 3,112 per aandeel betaald.
Under the terms of the amendment, the €10 million loan facility that was made available on the approval of BARHEMSYS® is terminated and replaced with a €10 million equity investment
at a price of €3.112 per share, which represents an approximately 4.1% premium to the closing share price on 29 May 2020 and equates to 3,213,769 shares to be issued to Cosmo.